prednisolone has been researched along with Acute Relapsing Multiple Sclerosis in 10 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Consensus may end there, as there is no clear-cut "best" route of administration or dosing schedule." | 2.45 | Relapse management in multiple sclerosis. ( Thrower, BW, 2009) |
| "Intracranial arachnoid cysts are rare but the widespread use of brain imaging has disclosed many asymptomatic cysts." | 1.36 | Asymptomatic supratentorial arachnoid cyst and symptomatic demyelination plaques: which one needs treatment? ( Amin, OS; Shwani, SS, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y | 1 |
| Wang, Q | 1 |
| Zeng, S | 1 |
| Zhang, Y | 1 |
| Zou, L | 1 |
| Fu, X | 1 |
| Xu, Q | 1 |
| Jasani, KM | 1 |
| Sharaf, N | 1 |
| Rog, D | 1 |
| Aslam, T | 1 |
| Liu, YH | 1 |
| Chan, J | 1 |
| Vaghjiani, V | 1 |
| Murthi, P | 1 |
| Manuelpillai, U | 1 |
| Toh, BH | 1 |
| Gaskin, JC | 1 |
| Coote, M | 1 |
| Thrower, BW | 1 |
| Simó, M | 1 |
| Amin, OS | 1 |
| Shwani, SS | 1 |
| Morrow, SA | 1 |
| Stoian, CA | 1 |
| Dmitrovic, J | 1 |
| Chan, SC | 1 |
| Metz, LM | 1 |
| Tu, CE | 1 |
| Young, YH | 1 |
| Gunal, DI | 1 |
| Afsar, N | 1 |
| Tuncer, N | 1 |
| Aktan, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)[NCT02258217] | 30 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients completed the ARMS survey after treatment for the new relapse.The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~The TCS score was calculated only for the time point after treatment of relapse. It was a sum of questions 4 (symptom improvement), 5 (ADL), and 6 (return to previous state of health (RSH)) were evaluated. Scores range from 0 to 30 units, with higher scores representing greater improvement/better functioning." (NCT02258217)
Timeframe: Follow-up visit
| Intervention | score on a scale (Mean) |
|---|---|
| Single Arm | 14.3 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, history of patients from the survey after treatment for the new relapse will be collected.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~ADL scores were calculated from Part 1 (new relapse), question 3 and Part 2 (after treatment of relapse), question 5 both specifically refer to ADL;~Scale: ADL (Activities of Daily Living) Minimum value: 0 Maximum value: 9 Higher scores indicated better functioning/ improvement." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| ADL (new relapse) | ADL (after treatment of relapse) | |
| Single Arm | 3.1 | 4.9 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~PCS was computed based on the sum of the ADL and RSH questions. The PCS was computed separately for Part 1 (new relapse) and Part 2 (after relapse treatment) and summarized descriptively; Higher scores indicating better functioning/greater improvement. The PCS scores were on a scale of 0 to 20 units." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| PCS (New relapse) | PCS (after treatment of relapse) | |
| Single Arm | 7.7 | 9.2 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse. The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~Part 1 (new relapse) & Part 2 (after treatment of new relapse), question 6 were used to calculate RSH;~Scale: RSH (Return to previous health) Minimum value: -1 Maximum value: 10 Higher scores indicating a more complete return to previous state of health." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| RSH (new relapse) | RSH (after treatment of new relapse) | |
| Single Arm | 4.6 | 4.4 |
"This scaling score is obtained by performing a neurologic exam with specific attention to eight different neurologic functional systems: visual, pyramidal, cerebellar, bowel and bladder, cerebral, brainstem, sensory and other (10). The score is rated from zero (normal neurologic examination) to ten (death due to MS). This is the standard neurologic disability scale used in clinical trials for the evaluation of disability in patients with MS.~These scores were compared between pre and post phase using paired t-tests." (NCT02258217)
Timeframe: baseline and at follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| EDSS score (new relapse) | EDSS score (after treatment of new relapse) | |
| Single Arm | 3.5 | 3.0 |
"Patients who reported a history of poor corticosteroid tolerability will be placed on Acthar and GASE scale will be given to assess tolerability to Acthar.~We listed the number of times a symptom was reported and was attributable to the ACTHAR treatment" (NCT02258217)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Headache | Dry Mouth | Dizziness | Tachycardia, palpitation or arrhythmia | Breathing problems | Abdominal pain | Nausea | Diarrhea | Reduced Appetite | Increased appetite | Difficulties with urination | Skin rash or itching | Tendency to develop bruises | Sweating | Hot flashes | Fatigue, loss of energy | Insomnia, sleeping problems | Nightmares or abnormal dreams | Back pain | Agitation | Irritability | Depressed Mood | Anxiety, fearfulness | Further symptoms | |
| Single Arm | 3 | 1 | 2 | 1 | 1 | 4 | 4 | 4 | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 2 | 8 | 2 | 1 | 6 | 6 | 3 | 1 | 8 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS and 9 questions assess the psychological impact of MS.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The score was on a scale of 9 to 45 points for MSIS psychological score.~Higher score indicate worse outcome." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MSIS psychological(new relapse) | MSIS psychological(after treatment of new relapse) | |
| Single Arm | 29.4 | 26.3 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS.~The physical impact of MS was compared between pre and post phase using paired t-tests. Each question is answered with points ranging from 1 to 5. Higher score indicates worse outcome. The total MSIS physical score ranges from 20 to 100 points with lower points indicating better impact." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Median) | |
|---|---|---|
| MSIS physical (new relapse) | MSIS physical (after treatment of new relapse) | |
| Single Arm | 58.5 | 56 |
"The Self-Administered Gerocognitive Exam (SAGE) is designed to detect early signs of cognitive, memory or thinking impairments. It evaluates your thinking abilities and helps physicians to know how well your brain is working.~It consists of 12 questions which are scored at different scales. The final SAGE score is calculated as a sum of these 12 questions and it ranges from 0 to 22.~Higher score indicates better outcome." (NCT02258217)
Timeframe: baseline and follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| SAGE (new relapse) | SAGE (after treatment of new relapse) | |
| Single Arm | 21 | 21 |
3 reviews available for prednisolone and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Case Report: Overlapping Multiple Sclerosis With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report and Review of Literature.
Topics: Adult; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Anticonvulsants; A | 2020 |
Relapse management in multiple sclerosis.
Topics: Adrenocorticotropic Hormone; Clinical Protocols; Demyelinating Diseases; Disease Management; Female; | 2009 |
[Therapy of multiple sclerosis].
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Diagnosis, Differ | 2009 |
1 trial available for prednisolone and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Area Under Curve; Biological Availability; Bi | 2004 |
6 other studies available for prednisolone and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Fingolimod-associated macular oedema.
Topics: Anti-Inflammatory Agents; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macula | 2017 |
Human amniotic epithelial cells suppress relapse of corticosteroid-remitted experimental autoimmune disease.
Topics: Amniotic Fluid; Animals; Antibodies, Anti-Idiotypic; Cell Proliferation; Cell- and Tissue-Based Ther | 2014 |
Postoperative cystoid macular oedema in a patient on fingolimod.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cataract Extraction; Diclofenac; Female; Fingolimod Hydroch | 2015 |
Asymptomatic supratentorial arachnoid cyst and symptomatic demyelination plaques: which one needs treatment?
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Arachnoid Cysts; Asymptomatic Diseases; Cereb | 2010 |
Audiovestibular evolution in a patient with multiple sclerosis.
Topics: Adult; Brain Stem; Cerebellum; Dominance, Cerebral; Dose-Response Relationship, Drug; Drug Administr | 2004 |
A case of multiple sclerosis with cerebral venous thrombosis: the role of lumbar puncture and high-dose steroids.
Topics: Adult; Cerebral Veins; Disability Evaluation; Drug Therapy, Combination; Female; Glucocorticoids; Hu | 2002 |